Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

Formulation differentiates therapies in crowded markets by improving adherence, tolerability, convenience, and delivery efficiency.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

Revolution Medicines’ breakthrough drug for pancreatic cancer was approved more than six months ahead of schedule.

The US FDA has approved ViiV Healthcare’s Tivicay PD, for use with other antiretroviral agents in paediatric patients with HIV-1 who weigh at least 2 kg.

The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials, the Asia-Pacific (APAC) region is now driving innovation ...

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.